158. 結節性硬化症 Tuberous sclerosis Clinical trials / Disease details
臨床試験数 : 112 / 薬物数 : 71 - (DrugBank : 19) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 118
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05323734 (ClinicalTrials.gov) | April 1, 2022 | 21/3/2022 | Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy | A Phase 3, Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults With Tuberous Sclerosis Complex (TSC)-Related Epilepsy (TrustTSC) | Tuberous Sclerosis Complex | Drug: Ganaxalone;Drug: Placebo | Marinus Pharmaceuticals | NULL | Recruiting | 1 Year | 65 Years | All | 162 | Phase 3 | United States;Canada;France;Germany;Israel;Italy;Spain;United Kingdom |